Search company, investor...
Chromotek company logo



Acquired | Acquired

Total Raised


About Chromotek

Chromotek is a company that develops and markets reagents for biomedical research. On October 20th, 2020, Chromotek was acquired by Proteintech. Terms of the transaction were not disclosed.

Headquarters Location

Am Klopferspitz 19

Planegg-Martinsried, 82152,


631 501 1058

Missing: Chromotek's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chromotek's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Chromotek

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Chromotek is included in 1 Expert Collection, including Advanced Materials.


Advanced Materials

1,282 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Chromotek Patents

Chromotek has filed 3 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Protein methods
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Proteins, Protein methods, Biotechnology, Transcription factors


Application Date


Grant Date



Related Topics

Molecular biology, Proteins, Protein methods, Biotechnology, Transcription factors



Latest Chromotek News

ChromoTek GFP-Trap Agarose affinity resin for IP of GFP-fusion proteins

Mar 31, 2023

Click2Contact The ChromoTek GFP-Trap provides fast and effective one-step immunoprecipitation of GFP-fusion proteins and their interacting factors from cell extracts or organelles. The product is produced in alpacas which possess heavy chain antibodies that are devoid of light chains and bind their antigen via a single variable domain (VHH), also known as a nanobody. These VHH domains have good binding properties and can be recombinantly expressed at a consistent high quality without batch-to-batch variation. GFP-Trap also displays high affinity to bind even low abundant proteins. ChromoTek nanobody-based reagents are thoroughly validated, recombinantly expressed and ready to use. Due to their size and single chain characteristic, they should provide a higher level of performance than conventional IgG antibodies in applications such as immunoprecipitation, immunofluorescence, live cell imaging, biosensor assays and protein purification. ChromoTek offers the GFP-Trap coupled to agarose beads, magnetic agarose beads or Dynabeads. For more information: .

Chromotek Frequently Asked Questions (FAQ)

  • Where is Chromotek's headquarters?

    Chromotek's headquarters is located at Am Klopferspitz 19, Planegg-Martinsried.

  • What is Chromotek's latest funding round?

    Chromotek's latest funding round is Acquired.

  • How much did Chromotek raise?

    Chromotek raised a total of $530K.

  • Who are the investors of Chromotek?

    Investors of Chromotek include Proteintech Group, High-Tech Grunderfonds and Bayern Kapital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.